S. Reid

发表

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific

L. Peng, Liang‐Kung Chen, Liang-yu Chen, 2017, BMC Infectious Diseases.

The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand.

S. Reid, P. Stehr-Green, S. Radke, 2008, Vaccine.

Pertussis continues to put New Zealand's immunisation strategy to the test.

C. Grant, S. Reid, 2010, The New Zealand medical journal.

The further and future evolution of the New Zealand Immunisation Schedule.

S. Reid, 2012, The New Zealand medical journal.

Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic

S. Crengle, D. Lennon, J. Stewart, 2012, Journal of paediatrics and child health.

Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.

D. Lennon, J. Stewart, S. Reid, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.

K. Mulholland, D. Lennon, S. Reid, 2005, Vaccine.

New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16–24 Months

K. Mulholland, S. Crengle, D. Lennon, 2007, The Pediatric infectious disease journal.

The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.

K. Mulholland, S. Crengle, D. Lennon, 2004, The New Zealand medical journal.

Immunogenicity and Tolerability in Infants of a New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine

K. Mulholland, D. Lennon, J. Stewart, 2009, The Pediatric infectious disease journal.

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.

K. Rasanathan, K. Mulholland, D. Lennon, 2006, Vaccine.

From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease.

K. Mulholland, D. Lennon, J. Stewart, 2005, Vaccine.

Post-Marketing Safety Monitoring of a New Group B Meningococcal Vaccine in New Zealand, 2004-2006

J. Neutze, S. Reid, P. Stehr-Green, 2007, Human vaccines.

Henoch-Schönlein purpura and meningococcal B vaccination

J. Neutze, S. Reid, P. Stehr-Green, 2008, Archives of Disease in Childhood.

Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand.

D. Lennon, I. Aaberge, S. Reid, 2004, The New Zealand medical journal.

Evolution of the New Zealand childhood immunisation schedule from 1980: a personal view.

S. Reid, 2006, The New Zealand medical journal.

VacciNews A JOINT PUBLICATION BY MERCK SHARP & DOHME AND THE ASIA-PACIFIC VACCINATION COUNCIL

Chin‐Yun Lee, S. Chan, A. Xu, 2002 .

Risk Factors and Immunity in a Nationally Representative Population following the 2009 Influenza A(H1N1) Pandemic

Q. S. Huang, M. Baker, D. Bandaranayake, 2010, PloS one.

Phase II meningococcal B vesicle vaccine trial in New Zealand infants

K. Mulholland, S. Crengle, D. Lennon, 2008, Archives of Disease in Childhood.

Control of pertussis.

D. Lennon, S. Reid, 1996, The New Zealand medical journal.

Pertussis control in New Zealand.

D. Lennon, S. Reid, O. Mansoor, 1994, The New Zealand medical journal.

Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers

D. Lennon, S. Reid, E. Ypma, 2011, Archives of Disease in Childhood.

Immunogenicity, Reactogenicity, and Safety of a P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to Preteens

K. Rasanathan, J. Hosking, S. Crengle, 2007, Clinical and Vaccine Immunology.